Form 4: Monopar COO Acquires Equity, Aligning Interests

Monopar Therapeutics' Chief Operating Officer, Andrew Cittadine, acquired stock options and restricted stock units on December 2, 2025, as part of an equity compensation plan.

Summary

• Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics (MNPR), acquired derivative securities on December 2, 2025.
• Cittadine was granted 8,969 stock options with an exercise price of $75.94 and an expiration date of December 2, 2035.
• These stock options are scheduled to vest 6/48ths on June 30, 2026, and 1/48th per month thereafter.
• Additionally, Cittadine acquired 13,919 Restricted Stock Units (RSUs) on the same date.
• The RSUs are scheduled to vest 6/48ths on June 30, 2026, and 3/48ths per quarter thereafter.
• Following these transactions, Cittadine beneficially owns 8,969 stock options and 52,593 Restricted Stock Units.

Sentiment

Score: 6

Explanation: The filing reports a standard equity grant to a key executive, which is generally viewed as a neutral to slightly positive event as it aligns management interests with shareholders. No negative information is present.

Positives

• The acquisition of stock options and restricted stock units by the Chief Operating Officer aligns management's interests with those of shareholders, promoting long-term value creation.
• Equity grants serve as a common and effective incentive for executive retention and performance within the industry.

Future Outlook

The vesting schedules for the stock options and restricted stock units extend into the future, with the first vesting event on June 30, 2026, and subsequent vesting continuing monthly for options and quarterly for RSUs. This structure indicates a long-term incentive and retention strategy for the Chief Operating Officer.

Industry Context

Equity compensation, including stock options and restricted stock units, is a standard practice in the biotechnology and pharmaceutical industries. This grant aligns Monopar Therapeutics with common industry compensation strategies designed to attract, retain, and incentivize key executives by linking their compensation to company performance.

Comparison to Industry Standards

• The utilization of stock options and restricted stock units for executive compensation is a widely accepted practice across the biotech and pharmaceutical sectors.
• This compensation mechanism is comparable to structures observed at major industry players such as Moderna, Pfizer, or Amgen, which frequently employ equity grants to align executive interests with long-term shareholder value.
• While specific details on the size of the grant relative to industry peers would necessitate a broader compensation analysis, the fundamental approach to executive incentives is consistent with global benchmarks.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Operating Officer's financial interests with the long-term performance of Monopar Therapeutics, potentially motivating decisions that enhance shareholder value.
• Employees: May signal stability in executive leadership and a commitment to long-term growth within the company.

Next Steps

• Vesting of 6/48ths of stock options and restricted stock units on June 30, 2026.
• Subsequent monthly vesting of 1/48th of stock options.
• Subsequent quarterly vesting of 3/48ths of restricted stock units.

Key Dates

Keywords

Monopar Therapeutics, MNPR, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Compensation, Andrew Cittadine, Executive Compensation